- Home
- PPC vs CORT Comparison
PPC vs CORT Comparison
Compare PPC & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PPC | CORT |
|---|---|---|
| Founded | 1946 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Meat/Poultry/Fish | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9B | 7.6B |
| IPO Year | 1987 | N/A |
Fundamental Metrics
Financial Performance| Metric | PPC | CORT |
|---|---|---|
| Price | $39.01 | $83.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $47.00 | ★ $139.00 |
| AVG Volume (30 Days) | ★ 1.2M | 637.8K |
| Earning Date | 10-29-2025 | 11-04-2025 |
| Dividend Yield | ★ 21.56% | N/A |
| EPS Growth | ★ 24.34 | N/A |
| EPS | ★ 5.16 | 0.87 |
| Revenue | ★ $18,351,780,000.00 | $741,172,000.00 |
| Revenue This Year | $3.98 | $23.79 |
| Revenue Next Year | $0.51 | $40.97 |
| P/E Ratio | ★ $7.55 | $95.78 |
| Revenue Growth | 1.76 | ★ 17.92 |
| 52 Week Low | $35.73 | $49.00 |
| 52 Week High | $57.16 | $117.33 |
Technical Indicators
Market Signals| Indicator | PPC | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 58.90 | 66.15 |
| Support Level | $37.17 | $77.55 |
| Resistance Level | $39.16 | $81.41 |
| Average True Range (ATR) | 0.83 | 2.72 |
| MACD | 0.25 | 0.77 |
| Stochastic Oscillator | 76.69 | 95.04 |
Price Performance
Historical ComparisonAbout PPC Pilgrim's Pride Corporation
Pilgrim's Pride is the second-largest poultry producer in the US (59% of 2024 sales), the UK (29% including other European sales), and Mexico (12%). Its UK and European arm also includes pork operations from the 2019 acquisition of Tulip. Pilgrim's sells to chain restaurants, food processors, food distributors, and retail chains. Most of its US and Mexican sales come from fresh chicken, while prepared chicken and pork constitute most of its UK and European sales. JBS owns more than 80% of Pilgrim's Pride's outstanding shares, though it failed to acquire the remaining stake in 2021 after a special board committee deemed that JBS' offer undervalued Pilgrim's Pride.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.